This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Trius Announces Positive Results From Phase 1 Lung Study Of Torezolid Phosphate

SAN DIEGO, Feb. 28, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections. In this study a 200 mg dose of torezolid phosphate was administered orally once-daily for three days to healthy adult volunteers. The trial achieved its primary goal of establishing the steady-state plasma pharmacokinetics and distribution of active drug into epithelial lining fluid (ELF). The same 200 mg once-daily dose of torezolid phosphate is currently being tested in a Phase 3 clinical trial for acute bacterial skin and skin structure infections (ABSSSI).

In the Phase 1 lung study, the exposure of torezolid in ELF was 48-fold higher than that achieved in plasma. This exposure was significantly above the minimum inhibitory concentration, MIC(90), for both Staphylococcus aureus (0.50 ug/mL) and Streptococcus pneumoniae (0.25 ug/mL) for the full daily dosing interval providing a pharmacokinetic rationale for the administration of a single 200 mg dose of torezolid phosphate every 24 hours for the treatment of lung infections caused by these pathogens. These results are consistent with those of prior animal studies that demonstrated considerable penetration of torezolid into lung fluids and tissues which translated into high efficacy in lung infections due to S. pneumoniae (penicillin-susceptible and -resistant) and S. aureus (methicillin-susceptible and -resistant) pathogens.

"Antibiotic penetration to the site of infection is a prerequisite for the effective treatment of pneumonia and this study clearly establishes that torezolid phosphate at the current 200 mg once-daily therapeutic dose is able to achieve a target exposure of drug expected to effectively treat lung infections," said Dr. David P. Nicolau, Principal Investigator of the study from the Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT. "The exposure ratio of torezolid into the ELF versus plasma was above values reported for linezolid, the first generation oxazolidinone, as well as above those reported for quinolone antibiotics, such as levofloxacin which is a mainstay of therapy for community and hospital acquired pneumonia."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.03 0.42%
FB $117.83 -0.62%
GOOG $695.73 -0.36%
YHOO $36.04 -1.30%
TSLA $233.28 -3.50%


Chart of I:DJI
DOW 17,698.80 -192.36 -1.08%
S&P 500 2,058.67 -22.76 -1.09%
NASDAQ 4,759.78 -57.8140 -1.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs